Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement
- Eva Van Braeckel1,2,
- Iain Page3,
- Jesper Rømhild Davidsen4,5,
- Christian B. Laursen4,5,
- Ritesh Agarwal6,
- Ana Alastruey-Izquierdo7,
- Aleksandra Barac8,9,
- Jacques Cadranel10,
- Arunaloke Chakrabarti11,
- Oliver A. Cornely12,13,14,15,
- David W. Denning16,
- Holger Flick17,
- Jean-Pierre Gangneux18,
- Cendrine Godet19,
- Yuta Hayashi20,
- Christophe Hennequin21,
- Martin Hoenigl22,23,
- Muhammed Irfan24,
- Koichi Izumikawa25,26,
- Won-Jun Koh27,
- Chris Kosmidis16,28,
- Christoph Lange29,30,31,32,
- Bernd Lamprecht33,
- Francois Laurent34,
- Oxana Munteanu35,
- Rita Oladele36,
- Thomas F. Patterson37,
- Akira Watanabe38 and
- Helmut J.F. Salzer33⇑ and for CPAnet
- 1Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
- 2Department of Internal Medicine and Paediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
- 3Regional Infectious Diseases Unit, NHS Lothian, Western General Hospital, Edinburgh, United Kingdom
- 4Pulmonary Aspergillosis Centre Denmark (PACD), Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark
- 5Odense Respiratory Research Unit (ODIN), Department of Clinical Research, University of Southern Denmark, Odense, Denmark
- 6Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
- 7Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain
- 8Clinic for Infectious and Tropical Diseases, University Clinical Centre of Serbia, Belgrade, Serbia
- 9Faculty of Medicine, University of Belgrade, Belgrade, Serbia
- 10Department of Pulmonology and Thoracic Oncology, APHP Hôpital Tenon and Sorbonne University, Paris, France
- 11Department of Medical Microbiology; Center of Advanced Research in Medical Mycology, Postgraduate Institute of Medical Education & Research, Chandigarh, India
- 12University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany
- 13University of Cologne, Faculty of Medicine and University Hospital Cologne, Chair Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany
- 14University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany
- 15German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany
- 16Manchester Fungal Infection Group, The University of Manchester, Manchester, United Kingdom
- 17Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
- 18Department of Parasitology and Mycology, Centre Hospitalier Universitaire de Rennes, Rennes, France
- 19Department of Pulmonology, AP-HP, Hôpital Bichat, Paris, France
- 20Department of Respiratory Medicine, Higashinagoya National Hospital, Nagoya, Japan
- 21Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Hôpital Saint-Antoine, Service de Parasitologie-Mycologie, Paris, France
- 22Division of Infectious Diseases and Global Health, University of California San Diego, La Jolla, California, USA
- 23Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Graz, Austria
- 24Section of Pulmonary and Critical Care Medicine, Department of Medicine, Aga Khan University, Karachi, Pakistan
- 25Department of Infectious Diseases, Nagasaki University Graduate School of Biomedial Sciences, Nagasaki, Japan
- 26Infection Control and Education Center, Nagasaki University Hospital, Nagasaki, Japan
- 27Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
- 28National Aspergillosis Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom
- 29Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
- 30German Center for Infection Research (DZIF), Germany
- 31International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany
- 32Department of Medicine, Karolinska Institute, Stockholm, Sweden
- 33Department of Pulmonology, Kepler University Hospital, Linz, Austria
- 34Department of Cardiothoracic Imaging, Hôpital du Haut Lévêque, CHU de Bordeaux, Pessac, France
- 35Division of Pneumology and Allergology, Department of Internal Medicine, State University of Medicine and Pharmacy “Nicolae Testemitanu”, Chisinau, Republic of Moldova
- 36Department of Microbiology, College of Medicine, University of Lagos, Lagos, Nigeria
- 37San Antonio Center for Medical Mycology, Division of Infectious Diseases, The University of Texas Health Science Center, San Antonio, Texas, USA
- 38Medical Mycology Research Center, Chiba University, Chiba, Japan
- Corresponding Author: Helmut J.F. Salzer (helmut.salzer{at}kepleruniklinikum.at)
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: R. Agarwal has received grants from Cipla Pharmaceuticals, India outside the submitted work. A. Alastruey-Izquierdo has received honoraria for lectures from Gilead and Pfizer. O.A. Cornely reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Al-Jazeera Pharmaceuticals, Astellas, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Pfizer; Payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Jannsen, MedPace, Paratek, PSI, Shionogi; A pending patent currently reviewed at the German Patent and Trade Mark Office; Other interests from DGHO, DGI, ECMM, ISHAM, MSG-ERC, Wiley. D.W. Denning and family hold Founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company; Acts or has recently acted as a consultant to Pulmatrix, Pulmocide, Zambon, Biosergen, TFF Pharmaceuticals, Bright Angel Therapeutics and Cipla; Sits on the DSMB for a SARS-CoV-2 vaccine trial; Honoraria for talks from Hikma, Gilead, BioRad, Basilea, Mylan and Pfizer. He is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group. H. Flick participated in the past 3 years on advisory boards from Boehringer-Ingelheim and INSMED and has received honoraria for lectures and travel support from Boehringer-Ingelheim, MSD, Roche, Novartis, AstraZeneca, GSK, Chiesi, Pfizer and GSK. C. Godet has received honoraria for lectures and travel support from Pfizer and MSD; fees for board memberships from SOS Oxygène and Pulmatrix; grant support from Ohre Pharma, Boerhringer-Ingelheim, Pfizer, MSD, SOS Oxygène, ISIS Medical, Vivisol, Elivie, CF Sante, Oxyvie LVL Medicaland and AstraZeneca; grant to the University of Poitiers from the French Ministry of Health for NEBULAMB and CPAAARI clinical trial. C. Hennequin has received funds for basic research from MSD; received travel grants from Pfizer and Gilead and has received honoraria for talks by Gilead. M. Hoenigl has received research funds from NIH, Gilead, Euroimmune, Astellas, Pfizer, F2G and MSD. K. Izumikawa has received research funds and speakers honoraria from Astellas Pharma Inc., Pfizer Japan Inc., MSD K.K. a subsidiary of Merck & Co., Inc., Asahi Kasei Pharma Cooperation and Sumitomo Dainippon Pharma Co., Ltd. C. Lange has received honoraria for talks from Chiesi, Gilead, Novartis, Oxfordimmunotec, Janssen and Insmed. T.F. Patterson has received grant support to UT Health San Antonio from Cidara, F2G and Gilead and was a consultant or served on data review committees for Appili, Basilea, Mayne, Merck, Pfizer, Scynexis and Sfunga. A. Watanabe has received research funding from Shionogi & Co. Ltd. and Eiken Chemical Co. Ltd. E. van Braeckel, I. Page, J.R. Davidsen, C.B. Laursen, A. Barac, J. Cadranel, J.P. Gangneux, Y. Hayashi, M. Irfan, W.J. Koh, C. Kosmidis, B. Lamprecht, F. Laurent, O. Munteanu, R. Oladele, A. Chakrabarti and H.J.F. Salzer have no conflict of interest.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received November 15, 2021.
- Accepted February 10, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org